IκK-16 decreases miRNA-155 expression and attenuates the human monocyte inflammatory response

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Excessive inflammation can lead to hypo-responsiveness, increasing infection risk and mortality.
• MicroRNAs (miRNAs), like miR-155, are key regulators of inflammatory pathways, including nuclear factor κB (NFκB).

Purpose of the Study:

• To investigate the impact of IκK-16, a selective inhibitor of IκK, on miRNA expression and monocyte inflammatory responses.
• To explore the role of miR-155 in the context of IκK inhibition and monocyte function.

Main Methods:

• Utilized a model of endotoxin tolerance with primary human monocytes.
• Assessed monocyte function, cytokine production (TNF-α, IL-10), and miRNA expression (miR-155, miR-138) with and without IκK-16 treatment.
• Employed miR-155 mimics and antagomirs to confirm the role of miR-155.

Main Results:

• Impaired monocytes showed decreased p65 expression and suppressed TNF-α and IL-10 production.
• miR-155 and miR-138 levels were significantly upregulated in impaired monocytes.
• IκK-16 treatment dose-dependently decreased miR-155 expression, along with TNF-α and IL-10 production.
• miR-155 mimics enhanced TNF-α production, while antagomirs reduced TNF-α and IL-10, confirming miR-155's role.

Conclusions:

• IκK-16 treatment effectively attenuates monocyte inflammatory responses.
• The anti-inflammatory effect of IκK-16 appears to be mediated, at least in part, through a miR-155-dependent mechanism.
• IκK-16 shows promise as a therapeutic strategy to control excessive innate inflammatory responses to lipopolysaccharide (LPS).